EC approves Biogen's ZURZUVAE as first oral treatment for postpartum depression

Investing.comWednesday, September 17, 2025 at 8:40:52 PM
EC approves Biogen's ZURZUVAE as first oral treatment for postpartum depression
The European Commission has approved Biogen's ZURZUVAE, marking a significant milestone as the first oral treatment for postpartum depression. This approval is crucial as it provides a new option for mothers experiencing this condition, which can severely impact their well-being and that of their families. With ZURZUVAE, patients may find relief in a more convenient form, potentially improving adherence to treatment and overall outcomes.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Trevi to present phase 2a trial data on chronic cough treatment at ERS
PositiveFinancial Markets
Trevi Therapeutics is set to present promising data from its phase 2a trial on a new treatment for chronic cough at the upcoming European Respiratory Society (ERS) conference. This is significant as chronic cough affects millions and finding effective treatments can greatly improve quality of life for patients. The presentation could also attract attention from investors and healthcare professionals, potentially leading to further advancements in respiratory therapies.
Cytokinetics’ SWOT analysis: aficamten’s potential reshapes HCM treatment stock outlook
PositiveFinancial Markets
Cytokinetics is making waves in the heart failure treatment landscape with its drug aficamten, which shows promising potential in reshaping hypertrophic cardiomyopathy (HCM) management. This development is significant as it could lead to improved patient outcomes and a positive shift in the company's stock outlook, reflecting investor confidence in innovative therapies. As the medical community looks for effective solutions for HCM, aficamten's success could mark a pivotal moment in treatment options.
Povorcitinib shows promising results for hidradenitis suppurativa
PositiveFinancial Markets
Povorcitinib has shown promising results in clinical trials for treating hidradenitis suppurativa, a chronic skin condition that affects many patients. This breakthrough could offer new hope for those suffering from this painful disease, as effective treatments have been limited. The positive outcomes from these trials highlight the potential for povorcitinib to improve the quality of life for patients, making it a significant development in dermatological care.
Brainsway stock surges after FDA clears accelerated depression treatment
PositiveFinancial Markets
Brainsway's stock price has surged following the FDA's approval of its accelerated treatment for depression. This breakthrough could provide new hope for patients struggling with this condition.
Editor’s Note: The FDA's clearance of Brainsway's treatment is significant as it may offer faster relief for those suffering from depression. This approval not only boosts the company's stock but also highlights advancements in mental health therapies.
Latest from Financial Markets
Bank of Japan Leaves Rates Unchanged, Announces ETF Sales
NeutralFinancial Markets
The Bank of Japan has decided to keep interest rates unchanged while it evaluates the potential impact of U.S. tariffs on the Japanese economy. This decision reflects a cautious approach as the central bank navigates uncertain economic conditions, highlighting the interconnectedness of global markets and the importance of monitoring external factors.
Stocks, Bonds Stories Need to Be Separated, Pendal Group Says
NeutralFinancial Markets
Amy Xie Patrick from Pendal Group emphasizes the need to differentiate between bonds and equities, suggesting that their performance is influenced by factors like tariffs. She reassures viewers that the Federal Reserve is not in a state of panic, providing a measured outlook on the markets. This perspective is important as it helps investors understand the current economic landscape and make informed decisions.
Indonesia’s Biggest Lender Cuts Loan Growth Target Amid Stimulus
NegativeFinancial Markets
Indonesia's largest lender, PT Bank Mandiri, has reduced its loan growth target for the year, even after receiving new government funds aimed at boosting lending and supporting the economy. This decision raises concerns about the overall economic outlook and the effectiveness of government stimulus measures.
Investors react to BOJ's decision to keep rates steady
NeutralFinancial Markets
Investors are closely monitoring the Bank of Japan's recent decision to maintain its current interest rates, a move that reflects the central bank's cautious approach to economic recovery. This decision is significant as it impacts financial markets and investor confidence, highlighting the ongoing challenges Japan faces in stimulating growth while managing inflation.
BOJ keeps interest rates steady, decides to start selling ETFs
NeutralFinancial Markets
The Bank of Japan (BOJ) has decided to maintain its current interest rates while also initiating the sale of exchange-traded funds (ETFs). This move is significant as it reflects the BOJ's ongoing strategy to manage economic stability and influence market conditions. By keeping interest rates steady, the BOJ aims to support growth, while the sale of ETFs indicates a shift in its approach to asset management, potentially impacting investors and the broader economy.
Soybeans Lead Rally for Grain Futures Before Trump-Xi Phone Call
PositiveFinancial Markets
US grain futures saw a significant rise on Friday, fueled by optimism surrounding an anticipated phone call between President Donald Trump and Chinese President Xi Jinping. Traders are hopeful that this conversation could lead to a resolution in the ongoing economic tensions between the two countries, which would be a positive development for the agricultural sector and the broader economy.